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betic wounds. Although some data support the use
of hyperbaric oxygen in patients with ischemic foot
ulcers that are not amenable to either bypass surgery
or angioplasty, there is a lack of evidence to support
its use in the management of neuropathic nonis-
chemic foot ulcers, the topic of this article. The fact
that the Center for Medicare and Medicaid Services,
as well as other insurance carriers, recognizes the
use of hyperbaric oxygen as an approved reim-
bursable treatment for problematic diabetic foot
wounds cannot be regarded as confirmation of ef-
ficacy. At present, the role of hyperbaric oxygen in
the management of purely neuropathic foot ulcer-
ation remains unsubstantiated.
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Spectrophotometry for Xanthochromia
to the editor: Xanthochromia, or a yellow appear-
ance of the cerebrospinal fluid, is often used to con-
firm suspected subarachnoid hemorrhage.1,2 It is
associated with the presence of bilirubin, a blood
product that arises only in vivo by the enzymatic
transformation of hemoglobin. However, visual as-
sessment of the cerebrospinal fluid for xanthochro-
mia is highly subjective and unreliable, especially in
cases in which other blood products, such as oxy-
hemoglobin, are present.1,2 The differential diag-
nosis may be further complicated by a high protein
level and a high cell count, as in meningitis and ne-
crosis, or by the presence of other pigments (namely,
carotenoids). To distinguish pigments in the cere-
brospinal fluid, such as bilirubin, that are clinically
important for diagnosing subarachnoid hemor-
rhage and other types of intracerebral bleeding from
those that are not important, objective spectropho-
tometry, rather than visual assessment, is recom-
mended. Because bilirubin has a characteristic sig-
nature — absorbance in the blue range (450 to 460
nm) — it can be readily identified by spectropho-
tometry. Moreover, by standard colorimetric proce-
dures, which have been established by the Com-
mission Internationale de l’Eclairage (CIE, or the



















































Figure 1. Chromaticity Diagram.
A section of the Commission Internationale de l’Eclair-
age (CIE) 1931 chromaticity diagram is shown, with the 
x–y chromaticity coordinates of 72 samples of cerebro-
spinal fluid containing bilirubin (yellow dots) with re-
spect to CIE illuminant D65 (white cross). For reference, 
the x–y chromaticity coordinates and the wavelengths 
of the spectral colors from 550 nm (corresponding to 
greenish yellow) to 620 nm (corresponding to red) are 
indicated. The region corresponding to pure yellow, 
which ranges between 575 and 580 nm (as noted by 
Petzold and Sharpe4), is shown in gray. The pie chart in-
dicates the proportions of samples visually identified as 
greenish, yellow (xanthochromic), and reddish by trained 
clinical observers. The full chromaticity diagram is 
shown in the lower left-hand corner.
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spectrophotometric trace can be converted to its
chromaticity coordinates.3 These procedures allow
the trace to be plotted in a geometric diagram (the
CIE 1931 chromaticity diagram for the 2-degree
field of view) and allow its dominant wavelength
(corresponding to hue) to be defined with respect to
average daylight conditions (CIE standard illumi-
nant D65) (Fig. 1).
Spectrophotometric analysis of 632 samples of
cerebrospinal fluid, obtained at the National Hospi-
tal for Neurology and Neurosurgery in London be-
tween January 1996 and April 2004, indicated that
72 contained bilirubin. Of these, only 15 (21 per-
cent) contained bilirubin alone and appeared pure
yellow (14 percent) or greenish yellow (7 percent)
(Fig. 1). A significantly higher number, 57 (79 per-
cent; chi-square=49.0, P<0.001), contained oxy-
hemoglobin as well as bilirubin. Their appear-
ance ranged from red and reddish pink to orange.
These findings reveal that about 80 percent of ce-
rebrospinal fluid samples containing substantial
amounts of bilirubin are not typically perceived as
xanthochromic (i.e., yellow). Equally important, the
presence of bilirubin cannot reliably be ruled out in
the case of cerebrospinal fluid samples that are vis-
ibly red.
In the United Kingdom, the rate of visual assess-
ment of the cerebrospinal fluid fell from 24 percent
to 6 percent, whereas the use of spectrophotometry
rose from 76 percent to 94 percent, after the intro-
duction of new guidelines for the detection of cere-
brospinal fluid pigments. This shift has reduced the
estimated error rate from 40 percent to 9 percent.5
Clearly, xanthochromia on the basis of mere visual
assessment is an ambiguous concept clinically,
physiologically, and biochemically. Two recent sur-
veys, however, have shown that visual assessment
of cerebrospinal fluid samples for xanthochromia
is still the most common method used in the United
States.2,6 We believe that this practice should imme-
diately be reevaluated.
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